title: Treatment of the acquired von Willebrand syndrome.
abstract: Acquired von Willebrand syndrome (aVWS) accounts for 22% of patients with abnormal von Willebrand factor. Most patients with known pathophysiological mechanisms suffer from cardiovascular, myeloproliferative and lymphoproliferative disorders. Less frequent associations are of autoimmune origin, due to hyperfibrinolysis, adsorption to tumor cells, reduced synthesis and prolonged circulation. The mechanisms leading to aVWS is hitherto not known in patients with liver and kidney diseases, drug use, glycogen storage disease, virus infections and at least 18 other disease entities. Diagnosis is complicated by the battery of tests needed, and their inherent rather low sensitivity and specificity for aVWS. Thus, even in acute bleeding situations it may take days until a firm diagnosis is settled and specific therapies can be initiated. The main aim is to shed more light onto this, compared with inherited von Willebrand disease, rare disease which affects at least 2-3% of the older population.
authors.affiliation: a Medilys Laborgesellschaft mbH, Hemostaseology, Paul-Ehrlich-Street 1, Hamburg, 22763, Germany.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Budde
authors.affiliation: a Medilys Laborgesellschaft mbH, Hemostaseology, Paul-Ehrlich-Street 1, Hamburg, 22763, Germany.
authors.forename: Sonja
authors.initials: S
authors.lastname: Scheppenheim
authors.affiliation: a Medilys Laborgesellschaft mbH, Hemostaseology, Paul-Ehrlich-Street 1, Hamburg, 22763, Germany.
authors.forename: Rita
authors.initials: R
authors.lastname: Dittmer
mesh_terms: D006801:Humans; D013577:Syndrome; D014842:von Willebrand Diseases / Q000188:drug therapy* / Q000473:pathology
keywords: acquired von Willebrand syndrome; cardiovascular diseases; hyperfibrinolysis; intravenous immunoglobulins; lymphoproliferative disorders; myeloproliferative disorders